Given the selective nature of current therapeutic candidates, metabolic stratification of lymphoma, such as classification into OXPHOS and BCR DLBCL subtypes, can sharpen patient selection and therapy matching, improve clinical utility by serving as predictive biomarkers, and accelerate translational adoption of mitochondrial-targeted strategies. The gene discussed is BCR; the disease is diffuse large B-cell lymphoma.